Evidence map›Paper›PMID 37637381›Full record

ArticleMolecular therapy. Methods & clinical development2023

Fully closed cell sorter for immune cell therapy manufacturing.

Masahiro Matsumoto, Shinji Tashiro, Tatsumi Ito, Kazuya Takahashi, Gakuji Hashimoto, Junji Kajihara, Yoshihiro Miyahara, Hiroshi Shiku, Yoichi Katsumoto

Abstract read
In one paragraph

Article in Molecular therapy. Methods & clinical development, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed.

  1. Review
  2. Programmable nanobody circuits for cell selection.bioRxiv : the preprint server for biology · 2026
    Article
  3. Article
  4. Article
  5. Review
  6. Article
  7. Article
  8. Preclinical evaluation of a novel CAR-T therapy utilizing a scFv antibody highly specific to MAGE-A4Molecular therapy : the journal of the American Society of Gene Therapy · 2024
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Masahiro MatsumotoTokyo Laboratory 11, R&D Center, Sony Group Corporation, Tokyo, Japan.
Shinji TashiroTokyo Laboratory 11, R&D Center, Sony Group Corporation, Tokyo, Japan.
Tatsumi ItoTokyo Laboratory 11, R&D Center, Sony Group Corporation, Tokyo, Japan.
Kazuya TakahashiTokyo Laboratory 11, R&D Center, Sony Group Corporation, Tokyo, Japan.
Gakuji HashimotoTokyo Laboratory 11, R&D Center, Sony Group Corporation, Tokyo, Japan.
Junji KajiharaTokyo Laboratory 11, R&D Center, Sony Group Corporation, Tokyo, Japan.
Yoshihiro MiyaharaDepartment of Personalized Cancer Immunotherapy, Mie University Graduate School of Medicine, Mie, Japan.
Hiroshi ShikuDepartment of Personalized Cancer Immunotherapy, Mie University Graduate School of Medicine, Mie, Japan.
Yoichi KatsumotoTokyo Laboratory 11, R&D Center, Sony Group Corporation, Tokyo, Japan.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

By analyzing patients treated with adoptive immune cell therapies, various immune cell phenotypes have been found in the starting and infused materials as determinants of sustained remission. The isolation of these specific phenotypes for clinical use requires current Good Manufacturing Practice (cGMP)-compliant cell-sorting technologies with multiparameter selection capabilities. Here, we developed a cGMP-requirement-applicable fully closed cell sorter that has a suction mechanism and multiparameter detection using two laser optical settings. Negative pressure generated by a change in the chamber volume at a sorting point allows the isolation of cells of interest with high viability and purity. Our study demonstrated that this microfluidic sorter enables the isolation of cells of interest at an effective rate of 7,000 sorts per second on average. A purity of 85.5% and 77.1% effective yield with 93.7% viability was obtained when applying a target population of 35.9% in total (lymphocyte+CD8+) at 15,000 events per second (2 × 10

Indexed as

cell purificationcell sortercell sortingcell therapycell therapy manufacturingcGMPflow cytometryfunctional assay

Identifiers

PMID37637381
PMCPMC10457513

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.